Drug resistance is a worldwide issue. In February 2017, WHO has released a list of 12 priority pathogens for which novel antibiotics are essential. Currently, most so-called new antibiotics are actually chemical modifications of existing ones. This only provides a short-term benefit leading to the emergence of further drug resistance. The issue is significant, because, the treatment options for these 12 families of priority pathogens are limiting.
Recently, in a report, WHO confirms that the world is running out of new antibiotics. And, it’s obvious that the development of new classes of antibiotics takes time. What is your take on managing the current drug resistance threat? Source: World Health Organization, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, 2017 Contagionlive
